ACR Convergence 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

AA

Alexion, AstraZeneca Rare Disease at ACR Convergence 2026

Nov 6–11, 2026 Orlando, FL ~15k attendees Website

Alexion, AstraZeneca Rare Disease brings 3 presentations to ACR Convergence 2026 in Orlando. Its program centres on rare disease, including ravulizumab in atypical hemolytic uremic syndrome, adult-onset hypophosphatasia symptoms and a properdin-targeting antibody in a vasculitis model.

OrganizationACR Convergence 2026 Attendance
AA
Alexion, AstraZeneca Rare Disease
Pharmaceutical companies
AstraZeneca's rare-disease medicines business, formerly Alexion Pharmaceuticals.
Poster
Tue Nov 10
10:30am–12:30pm

Explore the full ACR Convergence 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Orlando. Leave your work email and we’ll be in touch.

Privacy

Download the full ACR Convergence 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Alexion, AstraZeneca Rare Disease

Tell us what you sell and we’ll find the people at Alexion, AstraZeneca Rare Disease most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American College of Rheumatology (ACR). Organization details are derived from the ACR’s published program and exhibitor floor plan, and each organization’s own website. Submit a correction